Abstract Preimplantation genetic diagnosis (PGD) allows couples to avoid having a child with an inherited condition, potentially reducing cancer burden in families with a hereditary cancer predisposition. This study investigated and compared awareness and acceptance of PGD among patients with different hereditary cancer syndromes. Questionnaires were mailed to 984 adults with hereditary breast and ovarian cancer, Lynch syndrome, familial adenomatous polyposis, or multiple endocrine neoplasia type 1 or 2. Associations between clinical, demographic, and psychosocial factors and awareness and acceptance of PGD were examined. Of 370 respondents (38 % return rate), 28 % felt their syndrome impacted family planning, 24 % were aware of PGD, 72 % felt that PGD should be offered, 43 % would consider using PGD, and 29 % were uncertain. Family experience and syndrome-specific characteristics, such as disease severity, quality of life and availability of medical interventions as well as gender, family planning stage, and religiosity impact perceptions of the acceptability of PGD, though a high level of uncertainty exists. Hereditary cancer patients lack awareness of PGD despite feeling that PGD should be offered, highlighting the need for education on this topic. While we found attitudes about the acceptability of PGD to be generally similar to those reported in the literature and of genetics and ethics experts, we observed similarities and differences between syndromes that provide insight into why some hereditary cancer patients may find PGD more acceptable than others.
Introduction
Preimplantation genetic diagnosis (PGD) is an assisted reproductive technology (ART) that allows couples to avoid having a child with an inherited condition. PGD involves in vitro fertilization (IVF) and genetic testing to select embryos for uterine implantation that do not have the genetic disorder. Embryos with the mutation are discarded or stored long-term. PGD is technically possible for any single gene disorder. It has been used for more than a dozen hereditary cancer syndromes including adult-onset disorders such as hereditary breast and ovarian cancer and Lynch syndrome (LS) [1] . Ethical questions have been raised about the usage of PGD. It has been suggested that PGD be used only for the more severe diseases, with high penetrance, early age at onset, and for which few medical interventions are able to reduce disease risks [2] .
Approximately 5-10 % of all cancers are caused by autosomal dominant hereditary cancer syndromes, characterized by a high lifetime risk for one or more cancer types, young age of onset, high risk of second malignancies, and cancer occurring in successive generations of the family. Table 1 provides an overview of the five hereditary cancer syndromes most frequently encountered at our institution, their most commonly associated cancers, age of onset, and management options [3] [4] [5] [6] [7] [8] [9] [10] .
Hereditary breast and ovarian cancer (HBOC) and LS are adult-onset conditions with both surveillance and riskreducing surgical options for the most commonly associated cancers, although other cancers occur at lower frequencies which do not have effective surveillance or riskreduction options. Familial adenomatous polyposis (FAP) and multiple endocrine neoplasia types 1 and 2 (MEN1, MEN2) may have onset during childhood or adolescence. Prophylactic thyroidectomy is highly effective at addressing cancer risk in patients with MEN2; however thyroidectomized patients require lifelong thyroid hormone replacement and MEN2 patients are also at risk for pheochromocytoma and primary hyperparathyroidism which require lifelong biochemical surveillance. Some patients may require bilateral adrenalectomy which results in adrenal insufficiency and life-long dependence on steroids. MEN1 is associated mainly with benign conditions (hyperparathyroidism and pituitary adenomas). However, these may cause symptoms due to hormone overproduction and may require surgical or other treatment. There are no prophylactic surgical options that address the main cancer risks for patients with MEN1, though prospective monitoring and early surgical intervention for neuroendocrine tumors may positively impact survival, surgery is associated with high risk for pancreatic insufficiency and type 1 diabetes [11] . Most patients with FAP inevitably are recommended to undergo some form of colectomy to reduce colon cancer risk. Surgery is typically performed after the polyp burden becomes too high to manage effectively with endoscopy. Thus, the surgery typically occurs after the onset of disease and is not truly prophylactic. While regular endoscopy and surgery significantly improve overall survival, excess death rates still occur due to other FAPassociated tumors, such as duodenal carcinoma and desmoid tumors [12] . The implications of having a familial cancer syndrome make PGD a potentially attractive option for prevention of disease in future generations.
While a number of studies have been published about the attitudes of hereditary cancer patients toward PGD, they have mainly focused on HBOC and many included only women [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . In a recent meta-analysis of 13 studies published between 2005 and 2009 on attitudes toward PGD, awareness of PGD and acceptability of personal use of PGD was low (35 and 36 % of pooled respondents, respectively) while acceptability of PGD being offered to others was relatively high (71 %) [28] . PGD acceptability did not vary by study location (US vs. non-US) or syndrome; however the authors were limited in their ability to compare HBOC with other syndromes since only two studies of FAP and one of Li Fraumeni syndrome and von Hippel Lindau disease were included. Additionally, there were significant differences between study design and methods, including differences in whether the participants were confirmed to have a hereditary cancer syndrome and how much PGD was explained to them.
Patients may overestimate what PGD is able to accomplish, therefore, if PGD is not adequately explained in a study, it could bias overall acceptance rates [29] . The prevailing findings from these studies suggest that individuals with hereditary cancer syndromes who are in favor of PGD focus mainly on opportunity to have a healthy biological child; these people might otherwise forego childbearing due to risk of disease transmission. Individuals with less favorable attitudes emphasize the moral, religious, and ethical considerations of this technology. Associations between attitude toward PGD and religion, age, gender, education level, personal and family history of cancer, desire for more children, and prior awareness of PGD have been found, but vary between studies with no consistently predictive factors.
To our knowledge, no studies have directly compared attitudes toward PGD between individuals with different hereditary cancer syndromes. Such a comparison will add to the body of knowledge regarding hereditary cancer patients' perceptions of the acceptability of PGD, and identify whether there are syndrome-specific factors that influence attitudes toward PGD. In this study, the knowledge and acceptability of PGD of individuals with different hereditary cancer syndromes including HBOC, LS, FAP, MEN1, and MEN2 are examined.
Patients and Methods
Eligible participants included adults (ages 18 or older) who could read and write in English; who had a known deleterious mutation in any of the genes associated with HBOC (BRCA1 and BRCA2 genes), LS (MLH1, MSH2, MSH6, EPCAM, and PMS2 genes), FAP (APC gene), MEN1 (MEN1 gene), or MEN2 (RET gene). These syndromes were selected as they are the most frequently encountered syndromes at our institution. Participants were identified from a database maintained by the Clinical Cancer Genetics Program at the University of Texas M. D. Anderson Cancer Center and all had completed at least one visit with a genetic counselor at our institution between 1995 and 2011. This study was reviewed and approved by the M. D. Anderson Cancer Center Internal Review Board.
Eligible participants were mailed the study questionnaire. Non-responders received a second set of questionnaires 6 weeks after the initial mailing. The questionnaire was modeled after questionnaires from two previous studies on this subject and was tailored to the patient's cancer syndrome [29, 30] . The questionnaire was piloted on ten hereditary cancer patients. An informational paragraph about PGD was included that discussed IVF, embryo selection and transfer, cost, and the potential for multiple cycles to achieve a pregnancy and that pregnancy is not a guaranteed outcome. Educational websites were provided in case the participant wanted to learn more about PGD. Study questionnaires were deidentified. Unique tracking numbers were assigned so that questionnaire data could be linked with existing cancer and family cancer history data from the genetics database.
The three main outcomes of interest included: (1) whether the patient had heard of PGD before receiving the study questionnaire (yes or no), (2) whether the patient thought PGD should be offered to people with their hereditary cancer syndrome (yes, no, or unsure) and (3) whether they would personally consider using PGD (yes, no, or unsure). If the participant had already completed childbearing, we asked whether they would have considered it at the time they were planning a pregnancy. Predictors included demographic variables, personal history of cancer, syndrome, religiosity, number of children, whether those children were born before or after the diagnosis of the hereditary cancer syndrome, desire for additional children, and whether having a hereditary cancer syndrome has affected family planning decisions. We also grouped patients according to whether they had an adult versus childhood onset syndrome and based on the availability of a risk-reducing surgical management option.
Perceived severity of disease was rated using a five point Likert response scale from ''no impact'' to ''great impact'' on personal health and well-being. Agreement with 16 statements about ethical and practical aspects of PGD was measured using a five-point Likert response scale from ''strongly disagree'' to ''strongly agree''. The survey also assessed preferences for learning about PGD.
Pearson's Chi square test was used to assess the association of categorical predictive variables with the three outcomes of interest. If a cell had an N of B5, Fisher's exact test was substituted. Mann-Whitney's U test was used to evaluate the difference in the responses of the Likert scale questions for the three outcomes of interest. All analyses were performed using statistical analysis system (SAS) software (version 9.2; SAS Institute Inc, Cary, NC). All statistical tests were two-sided with alpha of p \ 0.05.
Results

Participant characteristics
Nine hundred eighty-four individuals met eligibility criteria and 370 completed the survey (38 % response rate). Non-responders were slightly younger than responders (47 vs. 50 years, p = 0.03), but otherwise had similar demographic and cancer histories and a similar response rate was observed between men and women. Table 2 provides an overview of the study population and their awareness and attitudes toward PGD. The majority of respondents were between the ages of 40 and 65, well-educated, married white women who considered themselves religious and had already completed childbearing. Median age at survey completion was 49 years (range 19-87). Respondents with a childhood-onset syndrome were younger than those with an adult-onset syndrome at the time of the survey (45 vs. 51 years, p = 0.04). Most of the respondents had borne children prior to finding out that they had a hereditary cancer syndrome, though 286 were diagnosed before completing childbearing. Of these, 28 % reported that the diagnosis affected reproduction. Thirteen were unable to have children because of the syndrome or cancer treatment. Twenty-one decided to have fewer children and 10 had children either earlier or later in life than anticipated. Nine chose not to have any children and one participant chose to adopt. Some respondents fell into more than one of the above categories and 25 did not provide a response. Most respondents (85 %) felt that a good quality of life was possible despite having a hereditary cancer syndrome; though 47 % reported feeling severely affected (reported a 4 or 5 on the disease severity scale) and 85 % believed that it was important that their child not inherit the syndrome. Actual disease severity scores did not predict perceived quality of life scores, but ratings of disease severity were higher in those whose syndrome had no available surgical risk-reduction (median score of 4 vs. 3; p = .045). Perceived quality of life scores were lower for patients with a childhood onset syndrome (median score of 4 vs. 5; p = .02).
PGD awareness
Twenty-four percent of respondents had heard of PGD before receiving the questionnaire. Higher levels of PGD awareness were associated with younger age, having a childhood-onset syndrome, income, and marital and childbearing status ( Table 2) . Respondents in the lowest income bracket were the least likely to know about PGD. Awareness was higher for individuals who were never married, did not have children before diagnosis, had not completed childbearing, and felt their syndrome affected reproductive planning. Genetic counselors were the preferred type of healthcare provider for discussions of PGD, with the next most preferred being the primary physician managing their syndrome.
PGD Acceptance
Overall, 72 % of the respondents felt that PGD should be offered to individuals with a hereditary cancer syndrome. Respondents who had a surgical risk-reducing option, considered themself religious, and who had at least one child at the time of the survey were less likely to agree that PGD should be offered (Table 2) .
Forty-three percent said they personally would consider using PGD, or would have if they had known about it at the time they were having children. Patients with MEN1 and FAP were the most likely to consider PGD. MEN2 patients were the least likely to consider PGD and HBOC patients had the highest level of uncertainty. Higher levels of personal acceptance were found in males and in individuals with a syndrome that has a childhood-onset or doesn't have a risk-reducing surgical option (Table 2 ). Higher perceived disease burden, but not actual cancer history, predicted higher levels of personal PGD acceptance. Additional factors associated with positive PGD attitudes included feeling strongly that their child should not inherit the syndrome, worry about blame, considering adoption, having spousal/family support, and feeling that PGD could lower the family's overall cost of healthcare (Table 3) . Negative attitudes were seen in those who felt that PGD interferes with nature and that good quality of life is attainable, despite the diagnosis of an inherited cancer syndrome (Table 3) .
Discussion
To our knowledge, this is the first study to systematically compare the awareness and attitudes of patients with different hereditary cancer syndromes about PGD and to explore what aspects of the syndrome may be influential in determining these attitudes. Awareness of PGD was similar across all four syndromes in our study. Younger age, having childbearing potential, the never married, and having a childhood-onset syndrome predicted PGD awareness. Patients diagnosed at young ages have longer to find out about PGD before the completion of childbearing. It is also possible that healthcare providers preferentially inform patients about PGD if they are at risk to pass on a childhood-onset syndrome; a 2009 French study surveying cancer geneticists' and prenatal diagnosis healthcare providers' attitudes about the acceptability of PGD for hereditary cancer showed that providers had more positive attitudes for situations in which the disease is severe and the onset is in childhood [31] . Additionally, patients were more likely to be aware of PGD if reproduction was affected. Patients may also be more likely to find out about PGD if they are seeking alternative family planning methods. Our study suggests that there may be differences in discussing PGD based on socioeconomic status, as patients with the lowest income were the least likely to be aware of PGD. It is possible that patients with lower incomes may have fewer resources in which to learn about PGD, or this may reflect a reluctance of healthcare providers to discuss this option with patients who they think will not be able to afford it. Preimplantation genetic diagnosis acceptance was not associated with personal history of cancer, which is consistent with the findings of several other studies [19, 21, 24, 26, 27, 29] , but not all [22] . PGD acceptance was associated with syndrome, age of syndrome onset, and perceived disease burden and the belief that a good quality of life is possible despite having the syndrome. Additionally, cancer history did not correlate with perceived severity of disease. This suggests that there may be unique aspects about each syndrome, rather than only the cancer risk, that impacts acceptability of PGD. The finding that individuals' perception of their disease, rather than actual disease history, may be more important in shaping attitudes about having a child with the disease and therefore influence thoughts about PGD, has been supported by other studies [13, 16, 19, 22, 29] . Perceived severity of disease may be shaped not only by personal experience with cancer/disease, but also by the experience of family members, witnessing death and suffering in the family, perceived acceptability and confidence in current management options, hope in future advancements in medicine, perceived ability to cope, and the degree to which difficulties were encountered finding a partner or deciding whether or not to have children [13, 16] .
We observed that disease burden was rated as more severe by those whose syndrome lacked a surgical riskreduction option; also, those with a childhood onset syndrome rated their syndrome as less compatible with a good quality of life. This finding could explain the observed differences in PGD acceptability between the different syndromes analyzed in our study. Patients with MEN2 had the lowest acceptance rate for PGD, in spite of being associated with the highest cancer risk of all of the syndromes and a syndrome of childhood onset. However, prevention or cure of thyroid cancer is high in MEN2 with early thyroidectomy, a procedure that is associated with a lower risk for adverse effects and psychological burden, relative to the surgeries required in the other syndromes (e.g. colectomy, mastectomy, or oophorectomy). MEN1 and FAP patients had the highest rates of acceptability of PGD; both are syndromes of childhood onset and their management requires technically more invasive procedures Feel strongly that child not inherit syndrome \.001
Would consider adoption \.001
Higher concern about blame \.001
Feel PGD could lower overall cost of family's healthcare \.001
Would have support of spouse and family \.001
Less likely to consider PGD Feel PGD interferes with nature \.001
Feel good quality of life is attainable with syndrome \.001
PGD preimplantation genetic diagnosis such as pancreatectomy or colectomy that are more likely to have a negative impact on quality of life. LS had the second lowest acceptance rate for PGD. The main cancer risks associated with LS also have a high potential for prevention through screening colonoscopy, hysterectomy and/or oophorectomy. Additionally, men with LS reduce most of their cancer risk through colonoscopy and do not require prophylactic surgery. Individuals with HBOC had the highest level of uncertainty about PGD. While cancer risks are drastically reduced through surgical intervention, bilateral mastectomy may have a negative impact on body image and sexuality and sequelae of bilateral salpingooohorectomy include infertility and premature menopause for some patients, which might explain why the rates of uncertainty were higher than patients with LS [32] .
Gender was the only demographic characteristic that predicted acceptance of PGD. The finding that men with hereditary cancer syndromes were more likely to accept PGD warrants further investigation, as this trend has been previously reported [29, 33, 34] . There are physical, and/or psychosocial variables that might explain this observation. For example, ART is significantly less invasive for men. While men are required to provide a semen sample, women must commit to multiple days of hormonal injections to stimulate the ovaries as well as invasive procedures for egg retrieval and embryo transfer. Other potential factors might include concern about exposure of cancer cells to the elevated estrogen levels achieved during ovarian hyperstimulation in women with HBOC, who may have or develop hormone-sensitive tumors. This was a found to be a deterrent to PGD in a previous study of women with HBOC [16] . It is also possible that males may be more accepting of PGD as a reproductive option in general; in a study of attitudes toward PGD in individuals with FAP, men were more likely to agree that it is important to have a genetically related child [29] . Additionally, a German study showed that men were more likely to approve of or undergo PGD for severe chronic disease or cancer predisposition than women [34] .
The only reproductive factors that were associated with PGD acceptance were whether the participant would consider adoption and whether they had at least one child. Individuals who would consider adoption may be more concerned about transmitting their syndrome to their children. Trends in our data suggest that individuals without biological children are more likely to believe that PGF should be offered while those who already have a child are more uncertain. The question of if and how the birth of a child impacts PGD attitudes warrant further investigation. It is possible that those who have a child focus more on the value and appreciation of that life, rather than transmission of a cancer syndrome and are thus less accepting of PGD. Alternatively, parents may worry about the possible psychological impact on an existing at-risk child if they choose to use PGD to have another child who will not be at risk for disease.
There are several limitations to this study, including a low (38 %) response rate despite two separate mailings. There were few participants with LS, FAP, MEN1, and MEN2 relative to HBOC. While we believe the respondents were representative of the overall MDACC hereditary cancer population and reassured that respondents and non-respondents demographic and cancer histories were similar, our study may have been underpowered to detect differences between these populations. The low response rate may be explained by the inherent difficulty in contacting former patients who were seen over a broad time period (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . The majority of the respondents were Caucasian (66 %), well-educated (60 % college graduates), and female (78 %) and all patients had received genetic counseling at MD Anderson Cancer Center. The high percentage of females likely reflects our large population of patients with HBOC since response rates were not different for males and females. Because there is not a uniform practice at our institution for discussion of PGD with hereditary cancer patients, there may also be bias introduced due to different genetic counseling practices in the various clinics that treat inherited syndromes, as well as differing practice patterns over the time period of the study. We also had a large proportion of respondents who had already completed childbearing (83 %) at the time of the survey, which may also add bias because they were asked to consider what they would have done retrospectively, even though their attitudes toward PGD were similar to respondents who had not completed childbearing. Additionally, it is well established that rates of intention to undergo genetic testing are higher than actual uptake; therefore, this study may overestimate the percentage of patients who would realistically pursue PGD.
We also acknowledge that the classification of syndromes as having a risk-reducing surgical option or not is somewhat problematic in the case of FAP. While colectomy is used in patients with FAP to reduce risk for cancer, we chose to classify FAP as a condition without a risk reducing surgery because these patients are typically undergoing surgery for a diseased organ (i.e. high polyp burden). While they do not yet have not cancer in many cases, we feel surgery to remove a diseased organ is a sufficiently different situation from surgery to remove a healthy organ that we believe our choice to classify FAP as we did is justified.
Our data suggest that most, but not all, hereditary cancer patients are interested in learning about PGD. We identified several factors associated with acceptance or rejection of PGD that parallel opinions of genetics and ethics experts such as consideration of disease severity, age of onset, and availability of medical interventions. However, gender, religiosity, previous childbearing experience, and family support may also play a role in shaping opinions.
Because most patients want to learn about PGD, healthcare providers should discuss the availability of ART with genetic testing with all hereditary cancer patients in an appropriate and sensitive manner, acknowledging that some do not condone the procedure. Consideration of PGD for hereditary cancer patients has been addressed and promoted in fertility preservation guidelines issued by the American Society for Reproductive Medicine and the American Society of Clinical Oncology [35, 36] . It is important to consider which healthcare provider(s) should approach patients with information about PGD. Patients most often preferred to have these discussions with a genetic counselor or with the primary physician managing their syndrome; however not all patients have access to a genetic counselor. Furthermore, previous data have suggested that physician knowledge of PGD for hereditary cancer is limited [37] . We observed a profound lack of awareness about PGD in this study population, thus continuing education is indicated to ensure that providers have sufficient knowledge about PGD so that patients can make informed decisions about whether to seek more indepth reproductive counseling. Our institution recently recruited a reproductive endocrinologist and infertility specialist to provide fertility preservation counseling and services to patients with cancer to optimize their reproductive health and current and/or future fertility. Specialty services such as this may be the ideal setting in which to have more detailed discussions about PGD with patients who have hereditary cancer syndromes. However, we also feel that PGD should also be discussed with patients who are beyond childbearing age, as they may have children or other younger relatives who may want to know about PGD but may lack access to counseling services.
While our findings that there is a lack of awareness about PGD and that there is a discrepancy between the percentage of patients who think PGD should be offered and those who would consider using it themselves are similar to findings from other studies, we observed similarities and differences between syndromes that provide additional insight into why some hereditary cancer patients may find PGD more acceptable than others. Data such as these not only aid in understanding the factors that influence individuals' attitudes toward PGD, but can significantly improve health care providers' ability to educate and identify patients who may benefit from PGD and anticipate potential concerns regarding this technology. This will facilitate appropriate referral of patients to genetic counselors and reproductive endocrinologists, who can provide more in-depth information about genetic testing.
